0000000001068441

AUTHOR

Salvatore Tumulo

showing 1 related works from this author

Scelte terapeutiche e trattamento con sorafenib nell'epatocarcinoma: Analisi finale dello studio GIDEON in Italia

2015

Summary. Introduction. Sorafenib, an oral multikinase inhibitor, is the only targeted agent approved for the treatment of patients with hepatocellular carcinoma (HCC) after demonstration to increase overall survival compared to placebo in two randomized phase III study. GIDEON (Global Investigation of therapeutic DEcisions in HCC and Of its treatment with sorafeNib) is the largest, global, non-interventional, prospective study of patients with uHCC (n>3200) treated with sorafenib in real-life clinical practice conditions. Here we report the final analysis of safety and efficacy in the Italian cohort of patients. Methods. Patients with unresectable HCC who are candidates for systemic ther…

Phenylurea CompoundAdultMaleNiacinamideCarcinoma HepatocellularHepatocellular carcinomaAntineoplastic AgentsAntineoplastic Agent80 and overHumansProspective StudiesAgedAged 80 and overGIDEON study; Hepatocellular carcinoma; Sorafenib; Adult; Aged; Aged 80 and over; Antineoplastic Agents; Carcinoma Hepatocellular; Female; Humans; Italy; Liver Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Prospective Studies; Medicine (all)Phenylurea CompoundsMedicine (all)CarcinomaLiver NeoplasmsHepatocellularSorafenibMiddle AgedProspective StudieHepatocellular carcinoma sorafenib GIDEON studyItalyLiver NeoplasmFemaleHumanGIDEON study
researchProduct